MX2020013014A - N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. - Google Patents

N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Info

Publication number
MX2020013014A
MX2020013014A MX2020013014A MX2020013014A MX2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A MX 2020013014 A MX2020013014 A MX 2020013014A
Authority
MX
Mexico
Prior art keywords
sup
benzamides
phenylsulfonyl
bcl
inhibitors
Prior art date
Application number
MX2020013014A
Other languages
English (en)
Inventor
Jianyong Chen
Shaomeng Wang
Original Assignee
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Regents filed Critical Univ Michigan Regents
Publication of MX2020013014A publication Critical patent/MX2020013014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente divulgación proporciona compuestos que tienen la Fórmula I-A: (ver Fórmula) y sus sales y solvatos aceptables desde el punto de vista farmacéutico, en donde A, X1, X2, X3 R1a, R1b, E, y (ver símbolo) son como se definen en la información de la memoria descriptiva. La presente divulgación también proporciona compuestos de la Fórmula I-A para usar en el tratamiento de una enfermedad, trastorno o afección que responda a la inhibición de la proteína Bcl-2, como el cáncer.
MX2020013014A 2016-08-05 2019-01-31 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. MX2020013014A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US201762454101P 2017-02-03 2017-02-03

Publications (1)

Publication Number Publication Date
MX2020013014A true MX2020013014A (es) 2021-02-22

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019001391A MX2019001391A (es) 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MX2020013014A MX2020013014A (es) 2016-08-05 2019-01-31 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019001391A MX2019001391A (es) 2016-08-05 2017-08-04 N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Country Status (26)

Country Link
US (3) US10829488B2 (es)
EP (3) EP3569601B1 (es)
JP (2) JP6651180B2 (es)
KR (2) KR102376764B1 (es)
CN (2) CN109311871B (es)
AU (2) AU2017305508B2 (es)
BR (1) BR112019001666A2 (es)
CA (1) CA3031419C (es)
CY (1) CY1123859T1 (es)
DK (1) DK3494115T3 (es)
ES (1) ES2849959T3 (es)
HR (1) HRP20202073T1 (es)
HU (1) HUE053414T2 (es)
IL (2) IL264059B (es)
LT (1) LT3494115T (es)
MX (2) MX2019001391A (es)
PE (1) PE20190711A1 (es)
PH (1) PH12019500231A1 (es)
PT (1) PT3494115T (es)
RS (1) RS61821B1 (es)
RU (3) RU2744358C2 (es)
SA (1) SA519401020B1 (es)
SG (2) SG11201900135YA (es)
SI (1) SI3494115T1 (es)
WO (1) WO2018027097A1 (es)
ZA (2) ZA201900240B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
MX2019001391A (es) * 2016-08-05 2019-06-06 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
EP3565815B1 (en) 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
RS63603B1 (sr) 2017-04-18 2022-10-31 Shanghai Fochon Pharmaceutical Co Ltd Sredstva za indukciju apoptoze
CA3098348A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
GEP20237458B (en) * 2018-07-31 2023-01-10 Ascentage Pharma Suzhou Co Ltd Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
UA125241C2 (uk) * 2018-07-31 2022-02-02 Есентейдж Фарма (Сучжоу) Ко., Лтд. СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP
CN110772521A (zh) * 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
CA3095699A1 (en) * 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
TWI732353B (zh) * 2018-11-23 2021-07-01 大陸商蘇州亞盛藥業有限公司 藥物組成物及其用途
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
WO2021000899A1 (en) * 2019-07-02 2021-01-07 Ascentage Pharma (Suzhou) Co., Ltd. A PHARMACEUTICAL COMBINATION CONTAINING mTOR INHIBITOR AND USE THEREOF
AU2020321068A1 (en) * 2019-07-31 2021-03-18 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
US20220317127A1 (en) * 2019-11-27 2022-10-06 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
US20220323465A1 (en) * 2019-12-04 2022-10-13 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2021113497A1 (en) 2019-12-06 2021-06-10 Loxo Oncology, Inc. Dosing of a bruton's tyrosine kinase inhibitor
US20230159518A1 (en) * 2020-03-06 2023-05-25 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline forms or amorphous forms of n-(phenyl sulfonyl) benzamide compounds or its salts or solvates
WO2021180040A1 (zh) * 2020-03-12 2021-09-16 南京明德新药研发有限公司 苯并五元环类化合物
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
EP4180422A4 (en) * 2020-07-10 2024-01-24 Jiangsu Hengrui Pharmaceuticals Co Ltd SULFONYL BENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PROCESS THEREOF AND USE THEREOF
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
CN114073703B (zh) * 2020-08-21 2022-12-30 苏州亚盛药业有限公司 用于治疗非酒精性脂肪肝炎的组合物和方法
EP4199924A1 (en) * 2020-08-21 2023-06-28 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating systemic lupus erythematosus
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
JP2024504542A (ja) * 2021-02-01 2024-02-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体
EP4319800A1 (en) 2021-04-07 2024-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CN117957018A (zh) 2021-08-02 2024-04-30 苏州亚盛药业有限公司 一种药物组合及其用途
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
MX2009002422A (es) 2006-09-05 2009-03-20 Abbott Lab Inhibidores bcl para tratar exceso de plaquetas.
BRPI0719563A2 (pt) 2006-12-04 2013-12-10 Abbott Lab Ensaios diagnósticos amigáveis para terapia de câncer
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP3101019A1 (en) 2008-12-05 2016-12-07 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3095784A1 (en) 2009-01-19 2016-11-23 AbbVie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN102388151A (zh) 2009-02-11 2012-03-21 雅培制药有限公司 用于鉴定、分类和监控具有bcl-2家族抑制剂抗性肿瘤和癌症的受试者的方法和组合物
CN109897038B (zh) * 2009-05-26 2022-04-05 艾伯维爱尔兰无限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
CN103167867B (zh) 2010-10-29 2016-12-21 Abbvie 公司 含有细胞凋亡诱导药剂的固体分散体
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
SI2642999T1 (sl) 2010-11-23 2017-01-31 Abbvie Ireland Unlimited Company Postopki zdravljenja z uporabo selektivnih Bcl-2 inhibitorjev
US10327687B2 (en) 2015-12-30 2019-06-25 Dexcom, Inc. System and method for factory calibration or reduced calibration of an indwelling sensor based on sensitivity profile and baseline model of sensors
MX2019001391A (es) 2016-08-05 2019-06-06 Univ Michigan Regents N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.

Also Published As

Publication number Publication date
ES2849959T3 (es) 2021-08-24
SA519401020B1 (ar) 2022-03-16
ZA201900240B (en) 2020-05-27
SG10201913643YA (en) 2020-03-30
KR20190035710A (ko) 2019-04-03
ZA201908466B (en) 2020-05-27
KR20210107170A (ko) 2021-08-31
CN110483501A (zh) 2019-11-22
EP3494115B1 (en) 2020-10-21
CA3031419C (en) 2021-08-24
AU2017305508B2 (en) 2021-01-07
DK3494115T3 (da) 2021-01-18
RU2722560C1 (ru) 2020-06-01
RS61821B1 (sr) 2021-06-30
US20190315739A1 (en) 2019-10-17
IL264059B (en) 2021-05-31
AU2021202113B2 (en) 2022-08-18
US20180354950A1 (en) 2018-12-13
EP3569601A2 (en) 2019-11-20
AU2017305508A1 (en) 2019-02-07
SI3494115T1 (sl) 2021-02-26
NZ750100A (en) 2021-01-29
RU2020114660A3 (es) 2020-09-15
US10829488B2 (en) 2020-11-10
RU2020134802A (ru) 2022-04-25
BR112019001666A2 (pt) 2019-05-28
WO2018027097A1 (en) 2018-02-08
HRP20202073T1 (hr) 2021-02-19
JP2020007311A (ja) 2020-01-16
EP3569601B1 (en) 2022-06-22
CA3031419A1 (en) 2018-02-08
EP3494115A1 (en) 2019-06-12
JP6651180B2 (ja) 2020-02-19
CY1123859T1 (el) 2022-05-27
US10221174B2 (en) 2019-03-05
KR102376764B1 (ko) 2022-03-18
IL282099B (en) 2022-03-01
RU2020114660A (ru) 2020-06-19
CN109311871B (zh) 2020-02-28
KR102429704B1 (ko) 2022-08-04
RU2744358C2 (ru) 2021-03-05
LT3494115T (lt) 2021-01-25
CN110483501B (zh) 2022-07-01
CN109311871A (zh) 2019-02-05
PT3494115T (pt) 2021-01-15
PE20190711A1 (es) 2019-05-17
IL264059A (en) 2019-01-31
US20210002277A1 (en) 2021-01-07
EP4129999A1 (en) 2023-02-08
SG11201900135YA (en) 2019-02-27
EP3569601A3 (en) 2019-11-27
MX2019001391A (es) 2019-06-06
JP7205903B2 (ja) 2023-01-17
HUE053414T2 (hu) 2021-06-28
AU2021202113A1 (en) 2021-05-06
IL282099A (en) 2021-05-31
PH12019500231A1 (en) 2019-07-29
US11718613B2 (en) 2023-08-08
JP2019527705A (ja) 2019-10-03

Similar Documents

Publication Publication Date Title
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
CR20200520A (es) Compuestos heterocíclicos como inmunomoduladores
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2017176957A8 (en) Mdm2 protein degraders
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
CR20200553A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2020001719A (es) Inhibidores macrocíclicos de mcl-1 y metodos de uso.
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12021550258A1 (en) Cdk8/19 inhibitors
TN2018000175A1 (en) Indane derivatives as mglur7 modulators
MX2022000103A (es) Compuestos para el tratamiento de trastornos oculares.
NZ750150A (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
TN2017000248A1 (en) Cgrp antagonist peptides
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.